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Abstract Using a cDNA gene expression array system, we
identified fra-1 as a novel target molecule for retinoid action in
the human pancreatic carcinoma cell line Dan-G. Retinoid
treatment resulted in a significant and time-dependent induction
of the fra-1 expression on the post-transcriptional level. Super-
shift assays revealed that fra-1 participates in the activator
protein 1 complex together with c-fos, c-jun and junB. Transient
transfection experiments using a reporter plasmid containing an
activator protein site upstream of the CAT reporter gene
revealed that the phorbolester-induced CAT activity was
suppressed by retinoids. Since fra-1 lacks a transactivation
function, we therefore suggest that the retinoid-mediated
induction of fra-1 might function as a negative regulator of the
activator protein 1 activity in human pancreatic carcinoma cells.
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1. Introduction
Retinoic acid (RA) modulates the cellular proliferation and
di¡erentiation in a variety of tissues in the adult organism as
well as during the embryogenesis and development [1]. These
pleiotropic e¡ects of RA are transduced by nuclear RA re-
ceptors (RAR K, L, Q) and retinoid X receptors (RXR K, L, Q)
which modulate gene expression through binding as ligand-
activated heterodimers to RA responsive elements (RARE),
located in the regulatory regions of target genes [2]. The anti-
proliferative e¡ects and the di¡erentiating action of retinoids
are thought to be mainly mediated through induction or re-
pression of RA responsive genes. A number of RA-regulated
genes have been characterized but attempts to identify genes
involved in the anti-proliferative e¡ects have so far been un-
successful in the majority of cell types and tissues [3,4].
We have previously demonstrated that retinoids inhibit
growth and induce cellular di¡erentiation in a broad panel
of human pancreatic carcinoma cells in vitro and in vivo [5^
7]. We were therefore interested to identify novel retinoid-
regulated genes in order to delineate the molecular targets
which are responsible for the anti-proliferative e¡ects of reti-
noids in pancreatic cancer cells. We used the Atlas cDNA
Expression Arrays to identify di¡erentially regulated genes
in the human pancreatic carcinoma cell line Dan-G. Here,
we present fra-1, a member of the fos protein family, as a
novel target molecule for retinoid action. Furthermore, we
provide evidence that retinoids might act as a negative regu-
lator of activator protein 1 (AP-1) action through induction of
fra-1 expression.
2. Materials and methods
2.1. Analysis of di¡erential gene expression
To identify retinoid-mediated di¡erences in gene expression, we
used the AtlasTM cDNA Expression Arrays (Clontech, Palo Alto,
CA, USA) according to the instructions of the manufacturer. Two
nucleic acid arrays include 588 human cDNAs spotted as duplicates
on a nylon membrane including several housekeeping genes as well as
plasmid DNAs to control for the hybridization intensity and speci¢c-
ity. PolyA RNA was isolated from DAN-G cells treated for 4 h
either with all-trans RA or vehicle (0.1% DMSO). After RNase-free
DNase I digestion, RNA was reverse-transcribed using the reagents
provided and [K-32P]dATP. The radioactively-labelled cDNA probes
were separately hybridized overnight to the Atlas Arrays. After a high
stringency wash, the hybridization pattern was analyzed by autora-
diography.
2.2. RNA isolation and Northern blot
PolyA-enriched RNA was extracted from DAN-G cells using the
PolyAT tract kit following the instructions of the supplier. For a
quantitative analysis, RNA was analyzed in a 1% agarose-2% form-
aldehyde gel, blotted onto Hybond N membranes (Amersham,
Braunschweig, Germany) and immobilized by UV crosslinking. Hy-
bridization was carried out using the full length human fra-1 cDNA,
ampli¢ed by RT-PCR using speci¢c 5P and 3P primers corresponding
to bases 29^48 and 870^899 (accession number X16707). Hybridiza-
tion was carried out using the QuickHyb reagent (Stratagene, Heidel-
berg, Germany).
2.3. Western blot analysis
Cell lysates were prepared using a bu¡er containing 1% SDS (w/v),
0.1 M Tris, pH 7.5, 0.05 M EDTA, 0.02 M EGTA, 0.1 M sucrose,
0.1 M L-mercaptoethanol and 1 mM phenyl-methyl-sulfonyl-£uoride
(PMSF). 20 Wg protein per lane was run on a 12% SDS-PAGE, trans-
ferred to nitrocellulose and probed with speci¢c polyclonal antibodies
(Santa Cruz, CA, USA). The detection was performed using a goat
anti-rabbit secondary antibody conjugated to horseradish peroxidase
(Dianova, Hamburg, Germany) and the ECL detection system (Amer-
sham, Braunschweig, Germany) or with an alkaline phosphatase con-
jugated anti-rabbit goat antibody (Promega, Heidelberg, Germany).
2.4. Electrophoretic mobility shift assay
Nuclear extracts from DAN-G cells were prepared by the micro-
preparation technique described by Andrews and Faller [8] and the
electrophoretic mobility shift assay was performed exactly as de-
scribed previously [9]. For supershift assays, 0.1 ng of polyclonal anti-
bodies speci¢c for c-Fos, FosB, Fra-1, Fra-2, c-Jun, JunB and JunD
were added to the reaction mixture and incubated for 2 h at 4‡C
before adding the 32P-labelled double-stranded oligonucleotide con-
taining the AP-1 consensus sequence: 5P-CTAGACTGAACGGT-
GACTCAAACTGCCGCTGCA-3P [10].
2.5. Nuclear run on transcription assay
Nuclei were prepared by sucrose gradient centrifugation. In vitro
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transcription, prehybridization and hybridization were carried out ex-
actly as previously described [9].
2.6. Transient transfections and CAT assay
Using the Lipofectamine Reagent (Gibco BRL, Bethesda, MD,
USA), DAN-G cells were transfected with 6 Wg of the MMP-1 (matrix
metalloprotease 1) promoter/CAT plasmid 3518/+63 and the mutant
construct 3518/+63-mTRE containing three base pair changes in the
AP-1 consensus sequence [11,12]. 12 h after transfection, cells were
incubated for 24 h with 1 WM 13-cis-RA, 0,1 WM 12-O-tetradecanoyl-
phorbol-13 acetate (TPA), or with a combination of 13-cis-RA and
TPA. The CAT activity was assayed using the CAT Enzyme Systems
(Promega, Heidelberg, Germany) following the instructions supplied
by the manufacturer.
3. Results
3.1. The retinoid-mediated induction of fra-1 expression
Using the Atlas cDNA Expression Arrays (Clontech Labo-
ratories, Palo Alto, CA, USA), we identi¢ed the fos-related
protein fra-1 which was speci¢cally up-regulated by ATRA in
the human pancreatic tumor cell line DAN-G within 4 h (data
not shown) as compared to vehicle-treated controls.
To con¢rm the retinoid-mediated induction of fra-1, we
performed Northern and Western blot analyses in DAN-G
cells. ATRA treatment resulted in a signi¢cant and time-de-
pendent increase of fra-1 mRNA and protein concentrations,
reaching a maximal induction at 24 h (Fig. 1). A prolonged
incubation for up to 48 h did not result in a further increase
of the fra-1 expression, neither did incubation with vehicle
alone (data not shown). In dose-response experiments, we
observed that 13-cis-RA, the stereoisomer of ATRA, was
equipotent in terms of the fra-1 induction as assessed by
Northern and Western blotting (data not shown).
To elucidate the mechanism of retinoid-induced fra-1 ex-
pression, we investigated the e¡ects of ATRA on the fra-1
gene transcription using a nuclear run on analysis. Neither
the fra-1 nor GAPDH gene transcription, which served as
an internal control, were altered by ATRA treatment at 4 h
or 24 h (Fig. 2), suggesting a primarily post-transcriptional
mechanism of induction.
3.2. Molecular constituents of the AP-1 complex in DAN-G
cells
To investigate which members of the jun and fos family
participate in the AP-1 complex formation in DAN-G cells,
we performed supershift assays using antibodies directed
against speci¢c components of the AP-1 complex and a spe-
ci¢c oligonucleotide containing the AP-1 consensus sequence.
To determine the speci¢city of binding to the AP-1 consensus
sequence, a 50^500-fold excess of unlabelled oligonucleotide
was added to the nuclear protein extracts prior to the addition
of labelled oligonucleotide. As seen in Fig. 3, the dimers bind-
ing to the AP-1 oligonucleotide are composed of c-fos, fra-1,
c-jun and junB proteins, fra-1 being the most prominent AP-1
component. In contrast, neither fosB, fra-2 or junD were de-
tected in the formation of the AP-1 complex in DAN-G cells.
3.3. E¡ects of ATRA on the protein expression of AP-1
components
To examine whether the retinoid-mediated induction of fra-
1 expression was selective for this AP-1 component, we inves-
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Fig. 1. E¡ects of ATRA on fra-1 expression in DAN-G cells.
DAN-G cells were incubated for the indicated time points with 10
WM ATRA. 1A: Northern blot. Shown is a representative of three
experiments. 1B: Western blot. Shown is a representative of two in-
dependent experiments yielding identical results. Controls were ana-
lysed in duplicate.
Fig. 2. E¡ects of ATRA on fra-1 gene transcription. DAN-G cells
were treated with 10 WM ATRA or vehicle either for 4 h or 24 h
and the fra-1 and GAPDH transcription were assessed by nuclear
run on analysis. Duplicates for each cDNA were slotted. Shown is
a representative of three independent experiments yielding identical
results.
Fig. 3. A supershift assay of AP-1 components in DAN-G cells.
Nuclear extracts were incubated with the radioactively labelled AP-1
consensus oligonucleotide together with speci¢c antibodies directed
against c-fos, fosB, fra-1, fra-2, c-jun, junB and junD. For competi-
tion experiments, a 50^500-fold excess of unlabelled oligonucleotide
was added.
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tigated the e¡ects of ATRA on the protein expression of the
other AP-1 constituents. A Western blot analysis revealed that
ATRA had no e¡ect on the c-fos, c-jun and junB expression
in DAN-G cells (Fig. 4), indicating that fra-1 is the only
component of the AP-1 complex that is regulated by retinoids.
3.4. RA inhibits TPA-stimulated AP-1 activity
To corroborate the functional signi¢cance of retinoid-medi-
ated up-regulation of fra-1 expression, we investigated the
AP-1 activity in DAN-G cells using transient transfection ex-
periments. As a reporter construct we used a 3518/+63-CAT
plasmid which contains an AP-1 site from the human MMP-1
gene upstream of the CAT gene [11,12]. Control cells were
transfected with the 3518/+63-mTRE-CAT plasmid which
contains three base pair changes in the AP-1 consensus se-
quence resulting in a loss of function. TPA stimulation for
24 h resulted in a signi¢cant increase of the CAT activity
compared to controls and cells incubated with 13-cis-RA
(TPA: 2.93U104 cpm, 13-cis-RA: 0.25U104 cpm, control:
0.17U104 cpm) (Fig. 5). The stimulatory e¡ect of TPA on
CAT was inhibited to approximately 50% by simultaneous
incubation of cells with 13-cis-RA (1.44U104 cpm). These
results indicate that retinoids inhibit the TPA stimulated
AP-1 transactivation activity in DAN-G cells.
4. Discussion
We have previously demonstrated that retinoid treatment
results in inhibition of growth and induction of cellular di¡er-
entiation in human pancreatic cancer cells in vitro and in vivo
[5^7]. These biological e¡ects of retinoids are based on a co-
ordinated regulation of gene expression. Therefore, the iden-
ti¢cation of retinoid responsive target genes which are in-
volved in the retinoid-mediated growth inhibition and
induction of di¡erentiation, is of particular interest in order
to further understand how these pleiotropic e¡ects of retinoids
are brought about.
Using the Atlas cDNA Expression Arrays, we have identi-
¢ed fra-1 as a novel target for the retinoid-regulated gene
expression. fra-1, along with c-fos, fosB and fra-2, belongs
to the family of fos-related genes [13,14]. These proteins func-
tion cooperatively as transcriptional regulators in a heterodi-
meric complex with the jun-related proteins c-jun, junB and
junD (reviewed in [15]). These dimeric AP complexes (AP-1)
interact with speci¢c DNA binding sites (TRE) to regulate the
transcription of genes, usually associated with the induction of
proliferation. The activity of AP-1 is therefore modulated by
various molecules involved in the growth regulation such as
growth factors, cytokines, oncogenes and tumor promoters
like TPA.
We observed a time-dependent induction of fra-1 mRNA
and protein levels by ATRA. A run on analysis revealed that
ATRA did not alter the transcription rate of the fra-1 gene
suggesting that retinoids post-transcriptionally increase the
fra-1 expression via an indirect mechanism. Post-transcrip-
tional modi¢cation of gene expression by retinoids has been
described in other systems and might, for example, involve
mRNA stabilization by various mechanisms [16]. To evaluate
if fra-1 expression plays a role in the AP-1 complex formation
in pancreatic carcinoma cells, we performed supershift assays.
We observed that c-fos and fra-1, in cooperation with c-jun
and junB, participate in the AP-1 complex in this cell line. In
addition, retinoids speci¢cally up-regulate the fra-1 expression
and had no e¡ect on the c-fos, c-jun and junB expression.
To investigate the biological consequence of fra-1 induction
by retinoids, we performed transactivation assays using a
transiently transfected reporter plasmid containing a function-
al TRE of the human MMP-1 promoter. We observed a pro-
nounced suppression of the TPA-stimulated CAT activity by
retinoids suggesting that the enhanced formation of fra-1/jun
heterodimers resulted in a less active AP-1 complex. Wisdom
and Verma [17] demonstrated that fra-1, unlike c-fos and
fosB, lacks a C-terminal transactivation domain as well as
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Fig. 5. E¡ects of RA on the TPA-stimulated CAT activity. DAN-G
cells were transiently transfected with the 3518/+63-CAT or 3518/
+63-mTRE-CAT reporter plasmid and incubated for 24 h with 1
WM 13-cis-RA, 0.1 WM TPA or 13-cis-RA plus TPA. The CAT ac-
tivity was determined by liquid scintillation counting and is ex-
pressed as cpm per 50 Wg protein. Shown are the mean and S.E.M.
of three independent experiments.
Fig. 4. E¡ects of ATRA on c-fos, c-jun and junB protein expres-
sion. DAN-G cells were incubated for the indicated time points
with 10 WM ATRA. Shown is a representative Western blot.
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N-terminal sequences with a transactivation function. More-
over, no transforming potential of fra-1 has been detected in
rat ¢broblasts. Hence, fra-1 is considered to be a negative
regulator of the AP-1 activity. Moreover, Suzuki et al. [18]
demonstrated that fra-1, like fra-2, is able to inhibit the AP-1-
dependent transactivation by c-fos and c-jun in transiently
transfected embryonal carcinoma cells. In addition, serum
growth factors stimulated the transcription of fra-1 with de-
layed kinetics relative to those of c-fos and fosB [19], suggest-
ing that one function of fra-1 might be to limit the transcrip-
tional activity of c-fos and fosB by sequestering jun partner
proteins into less active AP-1 complexes. However, in a mouse
mammary carcinoma cell line, fra-1 has been shown to induce
morphological transformation [20], suggesting the existence of
a species- and cell type-speci¢c biological function.
In summary, we have identi¢ed fra-1 as a novel target for
RA in human pancreatic carcinoma cells. Retinoid-mediated
induction of fra-1 might inhibit the AP-1 transactivation ac-
tivity. Therefore, in addition to the known antagonism be-
tween retinoids and AP-1 due to direct protein-protein inter-
action between retinoid receptors and AP-1 components
[21,22], induction of the fra-1 gene expression represents a
novel level of molecular interference between these two signal-
ling cascades.
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